Takeda announces topline results of phase 3 admire-cd ii trial of alofisel® (darvadstrocel) in complex crohn's perianal fistulas

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse: tak) today announced that the phase 3 admire-cd ii study, assessing the efficacy and safety of alofisel® (darvadstrocel) for the treatment of complex crohn's perianal fistulas (cpf), did not meet its primary endpoint of combined remission at 24 weeks, based on topline data. the safety profile for darvadstrocel was consistent with prior studies and there were no new safety signals identified. “while we are disappointed with.
TAK Ratings Summary
TAK Quant Ranking